Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13248524 | 0.88 | DCTPP1 (0.37) | BRD4POLBMEN1KMT2ACYP1A2 | |
| SCHEMBL12910648 | 0.78 | KDM4E (0.56) | BRD4POLBMEN1KMT2AMET | |
| SCHEMBL13248521 | 0.78 | SMN1; SMN2 (0.49) | BRD4MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL18352336 | 0.78 | ALDH1A1 (0.43) | MEN1KMT2ACYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL13248522 | 0.76 | POLB (0.44) | BRD4POLBMEN1KMT2AKDM4E | |
| SCHEMBL9924339 | 0.74 | BRD4 (0.42) | BRD4POLBMEN1KMT2ACYP1A2 | |
| SCHEMBL12891181 | 0.74 | BRD4 (0.42) | BRD4POLBMEN1KMT2ACYP1A2 | |
| SCHEMBL9924340 | 0.74 | BRD4 (0.42) | BRD4POLBMEN1KMT2AMET | |
| SCHEMBL13248528 | 0.74 | ALDH1A1 (0.40) | MEN1KMT2ACYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL903236 | 0.74 | ALDH1A1 (0.60) | CYP1A2KDM4ESMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | BRD4 224/4885POLB 3670/4885MEN1 2490/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | BRD4 224/4885POLB 3670/4885MEN1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.